However, published phase 3 papers focused primarily on total weight and glycemic control without reporting detailed body composition data comparing lean mass preservation between treatment groups
Because of their high stability, the production of supramolecular structures has garnered much interest in chemical materials, medications, sensors, etc
However, better delineation of the therapeutic and prophylactic roles of L-carnitine in these conditions will require further investigations in controlled, randomized and probably multicentre trials to evaluate the clinical value and the appropriate dosage of L-carnitine in each of these conditions
I believe the answer is emphatically yes: Its not deterministic, but its risk-associated, and you can alter your trajectory
FDA Registration No: 10-1-6200041784